Bullish
Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit and more
This article provides a comprehensive "Rx Rundown" of recent activities in the medical marketing and pharmaceutical sectors, including major deals, FD...
PFE
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (22)
Neutral (18)
Bearish (2)
Latest PFE News
Bullish
Bullish
Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI
Chai Discovery has announced a license agreement with Pfizer, providing the biopharmaceutical company with access to its AI platform, including the ad...
Neutral
Pfizer vs Merck: Chasing High Yield vs Higher Returns
This article compares Pfizer (PFE) and Merck (MRK) as investment opportunities, focusing on their dividend yields, growth prospects, and associated ri...
Neutral
Pfizer Oncology Deal And Lung Cancer Data Reshape Valuation Debate
Pfizer has entered a significant oncology partnership with Innovent Biologics, potentially worth up to $10.5 billion, focusing on early-stage cancer p...
Bullish
May Social Media Round-Up—ASCO, Q1 2026 Results, and More
This article provides a round-up of Pfizer's social media activity in May 2026, highlighting key events and announcements. It covers topics such as AS...
Bullish
Is Pfizer Stock a "Value Trap" or a Generational Opportunity?
Pfizer's stock has dropped over 50% from its 2021 high, trading below pre-pandemic levels due to factors like the end of the COVID vaccine boom and pa...
Bullish
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer announced that its BRAFTOVI regimen, when combined with cetuximab and FOLFIRI, nearly doubled the median progression-free survival in patients ...
Neutral
Insiders Aren’t Buying Pfizer Stock at $26 and That’s Actually a Good Thing
Despite a significant rally over the past year, Pfizer (PFE) insiders are not making large open-market purchases, which the article interprets as a po...
Neutral
Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $28
Wells Fargo has reaffirmed its "Hold" rating on Pfizer (PFE.US) and maintained a target price of $28. This indicates the firm's continued neutral stan...
Bearish
Barclays Maintains Pfizer(PFE.US) With Sell Rating, Maintains Target Price $25
Barclays has reiterated its Sell rating for Pfizer (PFE.US) and maintained its target price at $25. This indicates a continued bearish outlook on the ...
Neutral
Pfizer to Webcast Healthcare Conference Discussion
Pfizer announced it will webcast its discussion at an upcoming healthcare conference, making its insights and perspectives accessible to the public. T...
Bullish
UBS maintains Pfizer stock rating ahead of cancer drug trial results
UBS has reiterated a Neutral rating on Pfizer (NYSE: PFE) with a $27.00 price target as the company anticipates Phase III trial results for its cancer...
Bullish
UBS maintains Pfizer stock rating ahead of cancer drug trial results
UBS has reiterated a Neutral rating on Pfizer (NYSE:PFE) with a $27.00 price target as the company awaits Phase III trial results for its cancer drug ...
Neutral
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. is inviting the public to view and listen to a webcast of a discussion featuring Chairman and CEO Albert Bourla at the Jefferies Global He...
Bullish
Pfizer's BRAFTOVI® Becomes First Pfizer Therapy to Receive Priority Access Under Ontario's FAST Program, Accelerating Treatment for Canadians with Metastatic Colorectal Cancer
Pfizer Canada announced that BRAFTOVI® (encorafenib) will be funded under Ontario's FAST program, making it the first Pfizer therapy to receive priori...
Bullish
Pfizer's BRAFTOVI® Becomes First Pfizer Therapy to Receive Priority Access Under Ontario's FAST Program, Accelerating Treatment for Canadians with Metastatic Colorectal Cancer
Pfizer Canada announced that its therapy, BRAFTOVI® (encorafenib), will be funded under Ontario's Funding Accelerated for Specific Treatments (FAST) p...
Neutral
Pfizer Inc. $PFE Shares Bought by Arnhold LLC
Arnhold LLC grew its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 23.6% in the 4th quarter, according to its most recent disclosure w...
Neutral
Pfizer Inc. stock (US7170811035): Cancer focus and pipeline updates keep investors watching PFE
Pfizer Inc. is transitioning its business focus from pandemic-era successes to oncology, vaccines, immunology, and obesity treatments, maintaining its...
Bearish
Pfizer class action alleges website tracked users despite cookie opt-outs
A new class action lawsuit has been filed against Pfizer, alleging the company illegally tracked users' website activity and shared their data with th...
Bullish
Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A Efforts - Reiterate Buy (NYSE:PFE)
Pfizer (PFE) remains a "Great Buy" due to its aggressive M&A and R&D efforts, with newly launched products contributing significantly to revenue growt...
Research PFE on:
Ad Space